| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM198607173150301 |
| P698 | PubMed publication ID | 3523241 |
| P2093 | author name string | Braine HG | |
| Yeager AM | |||
| Burke PJ | |||
| Santos GW | |||
| Ambinder RF | |||
| Kaizer H | |||
| Saral R | |||
| Colvin OM | |||
| Stuart RK | |||
| Burns WH | |||
| P433 | issue | 3 | |
| P304 | page(s) | 141-147 | |
| P577 | publication date | 1986-07-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide | |
| P478 | volume | 315 |
| Q33449504 | A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia |
| Q36415142 | Acute leukemia: diagnosis, management, and potential for cure. |
| Q40837376 | Acute myeloid leukaemias |
| Q38785589 | Acute non-lymphoblastic leukemias in childhood |
| Q73127004 | Adult acute leukemia |
| Q39686022 | Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: current status |
| Q36415109 | Allogeneic and autologous bone-marrow transplantation. |
| Q34725758 | Antibody-based immunotherapy in high-risk neuroblastoma |
| Q36043413 | Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients |
| Q41735643 | Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up |
| Q80466932 | Autologous bone marrow transplantation for children with AML in first remission |
| Q33769677 | Autologous bone marrow transplantation in acute leukemia |
| Q40558267 | Autologous bone marrow transplantation in acute lymphoblastic leukaemia |
| Q39557751 | Autologous bone marrow transplantation in children |
| Q41148029 | Autologous graft-versus-host disease |
| Q38359403 | Autotransplants in leukaemia |
| Q36552133 | Bone Marrow Processing for Transplantation |
| Q41033249 | Bone marrow metastases |
| Q73544452 | Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel |
| Q39642636 | Bone marrow purging using monoclonal antibodies |
| Q38722211 | Bone marrow purging with mafosfamide--a critical survey |
| Q72660374 | Bone marrow transplantation |
| Q42579251 | Bone marrow transplantation as primary treatment of leukemia. |
| Q39523019 | Bone marrow transplantation for treatment of leukemia in children |
| Q68228709 | Bone marrow transplantation in India |
| Q39690644 | Bone marrow transplantation in the treatment of children with cancer. Current status. |
| Q33557804 | Bone marrow transplantation. Part II--autologous |
| Q36988384 | Cancer therapy: reimbursement of new therapeutic technologies |
| Q41715549 | Comparative cytogenetic analysis between cyclophosphamide-sensitive and -resistant lines of acute myeloid leukemia in the Lewis Brown Norway hybrid rat. |
| Q67849746 | Concentration of bone marrow mononuclear cells using a programmable blood cell separator |
| Q41586542 | Diagnosis and treatment of childhood acute myelogenous leukemia |
| Q50960006 | Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. |
| Q68327109 | Enrichment of Marrow Hemopoietic Progenitor Cells using a Blood Cell Processor |
| Q37732528 | Ex vivo and conditioning chemotherapy for autologous bone marrow transplantation |
| Q34306214 | Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas |
| Q70997282 | Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy |
| Q33572933 | Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers |
| Q36544454 | Hematopoietic Stem Cell Processing and Storage |
| Q73370287 | Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution |
| Q69962079 | In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging |
| Q43935092 | Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy |
| Q44849776 | Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia |
| Q40392434 | Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. |
| Q36883309 | Merocyanine 540 mediated photolysis of normal bone marrow, committed hemopoietic progenitors and neoplastic cells. implications for bone marrow purging. |
| Q72096735 | New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation |
| Q54307238 | Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF |
| Q72248798 | Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood |
| Q34320196 | Postremission therapy in adults with acute myeloid leukemia |
| Q37545966 | Practical aspects and diagnostic significance of in vitro manipulation of progenitors in human acute myeloid and lymphoid leukaemia |
| Q34720554 | Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker |
| Q39674385 | Prospects for cure in leukaemia |
| Q74455733 | Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8 |
| Q73586568 | Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging |
| Q40831551 | Role of autologous bone marrow transplantation for patients with acute and chronic leukemias. |
| Q40831567 | Role of autotransplantation in treatment of other solid tumors. |
| Q79172255 | Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis |
| Q44182687 | Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging |
| Q35189037 | Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant |
| Q39616826 | Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases |
| Q43918956 | Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging |
| Q40711599 | Techniques of harvesting and cryopreservation of stem cells. |
| Q35196479 | The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells |
| Q47617503 | The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia |
| Q72078948 | The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period |
| Q41283946 | The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). |
| Q40729492 | The use of monoclonal antibodies and immune markers in the diagnosis, prognosis, and therapy of acute leukemia. |
| Q34108102 | Therapy for acute myeloid leukemia: intensive timing of induction chemotherapy |
| Q46656673 | Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. |
| Q41055102 | Treatment and prognostic factors in acute myeloid leukaemia |
| Q37909059 | Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment |
| Q35169842 | Trying to Overcome Residual Disease After Bone Marrow Transplantation for Hematologic Malignancies |
| Q34539569 | Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? |
| Q46394773 | “Never been done before”—Consultative issues in innovative therapies |
Search more.